Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

8 results about "Iopamidol" patented technology

Iopamidol (INN, trade names Iopamiro, Isovue, Iopamiron, and Niopam) is a nonionic, low-osmolar iodinated contrast agent, developed by Bracco. It is available in various concentrations, from 200 to 370 mgI/mL.

Optimized process for preparation of iopamidol

The present invention relates to the field of organic chemistry, in particular to the synthesis of iodinated contrast agents. More specifically, the present invention relates to a sustainable process for the synthesis of iopamidol which allows for improved purity properties of the product and avoids the use of potentially dangerous reagents and solvents.
Owner:BRACCO IMAGING SPA

Developing agent and preparation method thereof, nonionic developing microsphere and preparation method and application thereof

The invention provides a developing agent which is modified iopamidol, a clinically safe nonionic hydrophilic developing agent iopamidol is subjected to structural modification, a hydrophilic side chain and a connecting arm are introduced, and the iopamidol is introduced into a gelatin degradable microsphere matrix with good biocompatibility in a covalent bonding manner; the degradable non-ionic X-ray developing microsphere with good biocompatibility is formed. Developing microspheres prepared by adopting the developing agent provided by the invention not only keep excellent X-ray developing performance, solve the problems of aggregation tendency and biocompatibility of traditional developing microspheres and realize real-time visual monitoring of an embolism process, but also have degradability and good biological safety, and are not only suitable for permanent embolism treatment, but also suitable for treatment of embolism. The solid developing embolism agent can also be expanded to the fields of temporary embolism, tissue engineering and the like, and the solid developing embolism agent with precise developing and safe degradation performance is provided for minimally invasive interventional therapy of diseases such as tumor intervention and vascular malformation.
Owner:SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY

A method for simultaneously degrading iodine source pollutants and adsorbing and removing iodine products by catalyzing PMS based on ferric chloride and biochar

PendingCN122324949AIodate saltIron chloride
This application relates to the field of water treatment technology, specifically a method for the simultaneous degradation of iodine-based pollutants and adsorption removal of iodine products using ferric chloride and biochar-catalyzed PMS. The method includes the following steps: S1, adding iodine-based pollutants to water, replenishing water, and adjusting the pH to obtain a simulated polluted water sample; S2, under stirring conditions, adding biochar, ferric chloride solution, and PMS solution to the simulated polluted water sample obtained in step S1 to obtain a reaction solution, allowing the mixture to react, standing to precipitate, and collecting the supernatant. This method achieves a removal rate of over 96% for iopamidol, and the content of iodide ions and iodates in the polluted water sample is extremely low.
Owner:XIAMEN UNIV OF TECH

Novel vascular embolization compositions comprising biocompatible polymers and methods of making the same

The present application relates to the technical field of embolic material, in particular to a vascular embolization composition containing a biocompatible polymer and a preparation method thereof, comprising a biocompatible polymer and a biocompatible iodine-containing contrast agent; the biocompatible polymer is selected from polylactic acid-glycolic acid copolymer PLGA, polycaprolactone PCL, polyethylene glycol-polylactic acid copolymer PEG-PLA or polytrimethylene carbonate PTMC; the biocompatible iodine-containing contrast agent is selected from triiodophenoxy ethyl acrylate-hydroxyethyl methacrylate copolymer, iohexol, triiodophenol, iopromide or iopamidol; the biocompatible iodine-containing contrast agent is used to avoid metal toxicity, has high and uniform development intensity, meets clinical precise positioning, and has good compatibility and dispersibility.
Owner:SHANGHAI YISIMIAO MEDICAL INSTR CO LTD

Preparation method of chlorodiiodo isophthalein acyl chloride and application of chlorodiiodo isophthalein acyl chloride in preparation of iopamidol impurity H

The invention discloses a preparation method of chlorodiiodo isophthalein acyl chloride and application of the chlorodiiodo isophthalein acyl chloride in preparation of an iopamidol impurity H. The method comprises the following steps: reacting diiodo-isophthalic acid with an acylating chlorination reagent to obtain diiodo-isophthalein acyl chloride, and then carrying out chlorination reaction on the diiodo-isophthalein acyl chloride and N-chlorosuccinimide (NCS) in an organic solvent to prepare a key intermediate chlorinated diiodo-isophthalein acyl chloride; further taking the intermediate as a raw material, acylating, and carrying out amidation and hydrolysis reaction with serinol to prepare the iopamidol impurity H. According to the method disclosed by the invention, through a strategy of firstly performing acylating chlorination and then performing chlorination, the defects of difficulty in direct chlorination reaction of diiodo isophthalic acid and poor regioselectivity of a conventional route are effectively overcome, and the method has the advantages of short synthesis route, high total yield, mild reaction conditions, simplicity and convenience in post-treatment and the like; the method is suitable for industrially preparing high-purity impurity reference substances.
Owner:ZHEJIANG STARRY PHARMA +2

Synthesis of non-ionic radiographic contrast agents by reactive extrusion

PendingCN121620501AOrganic compound preparationCarboxylic acid amides preparationRadiographic contrast mediaRadiographic Contrast Agent
The invention relates to the industrial preparation of non-ionic X-ray contrast agents. In particular, the present invention relates to a process for the synthesis of iopamidol using a continuous reactive extrusion process which enables efficient conversion of the relevant key intermediates, preferably in the absence of any solvent. The invention also relates to the preparation of radiographic X-ray contrast agents or key intermediates thereof by using reactive extrusion techniques.
Owner:BRACCO IMAGING SPA

Iopamidol injection and a preparation method thereof

The present application relates to the technical field of pharmaceutical preparation, in particular to a iopamidol injection and a preparation method thereof.The iopamidol injection comprises iopamidol, glycine, sodium citrate, a pH regulator and water for injection, and the pH regulator makes the pH value of the injection be 6.5-7.5.Compared with the prior art, the iopamidol injection of the present application has good stability, can withstand high-temperature sterilization, and avoids the use of aminotriol and calcium disodium edetate, and has good safety; compared with the same specification reference preparation, the iopamidol injection prepared by the present application has reduced viscosity, and improves the compliance of clinical application.
Owner:HAINAN PULIN PHARMA

Preparation method of iopamidol

The invention relates to a preparation method of iopamidol. Specifically, the invention provides a preparation method of iopamidol, and the method comprises the following steps: mixing a compound 2, a compound 3 and an organic solvent, carrying out amidation reaction, sequentially adding water and concentrated hydrochloric acid, carrying out stirring reaction, adding a sodium hydroxide aqueous solution, carrying out hydrolysis reaction, then adding dichloromethane for extraction, desalting a water phase through an electrodialysis method, and obtaining the iopamidol. And concentrating the desalted water phase under reduced pressure to obtain an oily substance, adding ethanol, heating and refluxing, cooling and crystallizing, filtering, and drying a filter cake under reduced pressure to obtain iopamidol. The iopamidol prepared by the method disclosed by the invention has excellent purity and yield, and the method disclosed by the invention is simple in process and operation and beneficial to industrial amplified production.
Owner:ZHEJIANG HISYN PHARMA